MEK Inhibitor, TAK-733 Reduces Proliferation, Affects Cell Cycle and Apoptosis, and Synergizes With Other Targeted Therapies in Multiple Myeloma

Blood Cancer J. 2016 Feb 26;6(2):e399. doi: 10.1038/bcj.2016.7.

Publication types

  • Letter
  • Research Support, N.I.H., Extramural

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Apoptosis / drug effects*
  • Cell Cycle / drug effects*
  • Cell Proliferation / drug effects
  • Drug Resistance, Neoplasm
  • Drug Synergism
  • Humans
  • Molecular Targeted Therapy
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / metabolism*
  • Protein Kinase Inhibitors / pharmacology*
  • Protein Kinase Inhibitors / therapeutic use*
  • Pyridones / pharmacology*
  • Pyridones / therapeutic use*
  • Pyrimidinones / pharmacology*
  • Pyrimidinones / therapeutic use*
  • Treatment Outcome

Substances

  • Protein Kinase Inhibitors
  • Pyridones
  • Pyrimidinones
  • TAK 733